Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimos D Mitsikostas

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Current Opinion in Neurology|March 2, 2016
Nocebo in headacheDimos D Mitsikostas
Current Neurology and Neuroscience Reports|December 24, 2011
Nocebo in headaches: implications for clinical practice and trial designDimos D Mitsikostas
The Lancet. Neurology|May 20, 2023
Rimegepant for migraine: acute efficacy beyond the USADimos D Mitsikostas
Nature Reviews. Neurology|October 7, 2024
Continuing evolution of migraine-specific therapies - targeting migraine with precision and persistenceDimos D Mitsikostas, Alan Rapoport
Therapeutic Advances in Neurological Disorders|May 20, 2020
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trialsPanagiotis Gklinos, Dimos D Mitsikostas
Current Opinion in Neurology|February 28, 2017
Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studiesDimos D Mitsikostas, Uwe Reuter
Pharmaceuticals (Basel, Switzerland)|April 3, 2021
The Role of Galcanezumab in Migraine Prevention: Existing Data and Future DirectionsPanagiotis Gklinos, Dimos D Mitsikostas
CNS & Neurological Disorders Drug Targets|August 19, 2007
The role of glutamate and its receptors in migraineMichail Vikelis, Dimos D Mitsikostas
Multiple Sclerosis and Related Disorders|May 5, 2018
Reply to Tsivgoulis and colleagues commentsDouglas S Goodin, Dimos D Mitsikostas
Central Nervous System Agents in Medicinal Chemistry|September 1, 2012
Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the futureDimos D Mitsikostas, Peer Tfelt-Hansen
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Current Opinion in Neurology|March 2, 2016
Nocebo in headacheDimos D Mitsikostas
Current Neurology and Neuroscience Reports|December 24, 2011
Nocebo in headaches: implications for clinical practice and trial designDimos D Mitsikostas
The Lancet. Neurology|May 20, 2023
Rimegepant for migraine: acute efficacy beyond the USADimos D Mitsikostas
Nature Reviews. Neurology|October 7, 2024
Continuing evolution of migraine-specific therapies - targeting migraine with precision and persistenceDimos D Mitsikostas, Alan Rapoport
Therapeutic Advances in Neurological Disorders|May 20, 2020
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trialsPanagiotis Gklinos, Dimos D Mitsikostas
Current Opinion in Neurology|February 28, 2017
Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studiesDimos D Mitsikostas, Uwe Reuter
Pharmaceuticals (Basel, Switzerland)|April 3, 2021
The Role of Galcanezumab in Migraine Prevention: Existing Data and Future DirectionsPanagiotis Gklinos, Dimos D Mitsikostas
CNS & Neurological Disorders Drug Targets|August 19, 2007
The role of glutamate and its receptors in migraineMichail Vikelis, Dimos D Mitsikostas
Multiple Sclerosis and Related Disorders|May 5, 2018
Reply to Tsivgoulis and colleagues commentsDouglas S Goodin, Dimos D Mitsikostas
Central Nervous System Agents in Medicinal Chemistry|September 1, 2012
Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the futureDimos D Mitsikostas, Peer Tfelt-Hansen
Pageof 10